GENNEX LABORATORIES
|
GENNEX LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.34 | 0.32 | 0.32 | 0.15 | 0.18 |
| CEPS(Rs) | 0.32 | 0.36 | 0.37 | 0.22 | 0.24 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 3.95 | 3.46 | 3.14 | 2.82 | 2.67 |
| Tax Rate(%) | 22.79 | 22.98 | 20.23 | 27.16 | 26.64 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 6.53 | 8.24 | 10.26 | 5.42 | 6.71 |
| EBIT Margin(%) | 10.75 | 9.15 | 9.12 | 5.51 | 6.37 |
| Pre Tax Margin(%) | 8.87 | 7.80 | 7.95 | 4.25 | 5.05 |
| PAT Margin (%) | 6.85 | 6.01 | 6.34 | 3.10 | 3.70 |
| Cash Profit Margin (%) | 8.13 | 7.22 | 7.73 | 4.77 | 5.35 |
| Performance Ratios | |||||
| ROA(%) | 4.92 | 6.18 | 6.97 | 3.42 | 4.35 |
| ROE(%) | 8.55 | 9.39 | 10.71 | 5.34 | 6.77 |
| ROCE(%) | 10.84 | 11.82 | 13.24 | 8.36 | 10.52 |
| Asset Turnover(x) | 0.72 | 1.03 | 1.10 | 1.10 | 1.17 |
| Sales/Fixed Asset(x) | 1.18 | 2.14 | 2.10 | 1.99 | 2.04 |
| Working Capital/Sales(x) | 3.90 | 2.91 | 3.67 | 4.25 | 5.11 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.85 | 0.47 | 0.48 | 0.50 | 0.49 |
| Receivable days | 49.44 | 51.46 | 39.96 | 50.76 | 63.48 |
| Inventory Days | 59.51 | 35.67 | 35.71 | 38.85 | 23.33 |
| Payable days | 67.75 | 65.55 | 71.92 | 88.41 | 113.41 |
| Valuation Parameters | |||||
| PER(x) | 16.32 | 22.14 | 11.69 | 12.10 | 16.90 |
| PCE(x) | 17.31 | 20.22 | 10.06 | 8.22 | 12.27 |
| Price/Book(x) | 1.42 | 2.17 | 1.25 | 0.66 | 1.16 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.58 | 1.59 | 0.93 | 0.50 | 0.73 |
| EV/Core EBITDA(x) | 11.96 | 14.36 | 7.90 | 6.57 | 8.48 |
| EV/EBIT(x) | 13.38 | 16.26 | 9.60 | 8.36 | 10.66 |
| EV/CE(x) | 0.78 | 1.43 | 0.95 | 0.48 | 0.79 |
| M Cap / Sales | 1.54 | 1.56 | 0.83 | 0.42 | 0.71 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 7.17 | 2.62 | 7.25 | -0.33 | 27.47 |
| Core EBITDA Growth(%) | 27.91 | -4.23 | 68.10 | -12.63 | 55.21 |
| EBIT Growth(%) | 29.41 | 2.85 | 75.81 | -13.58 | 74.92 |
| PAT Growth(%) | 25.43 | -2.85 | 117.53 | -16.41 | 165.71 |
| EPS Growth(%) | 5.94 | 1.66 | 117.59 | -16.43 | 165.58 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.24 | 0.23 | 0.19 | 0.14 | 0.13 |
| Current Ratio(x) | 1.62 | 1.93 | 1.91 | 1.68 | 1.68 |
| Quick Ratio(x) | 1.09 | 1.61 | 1.65 | 1.32 | 1.37 |
| Interest Cover(x) | 5.71 | 6.80 | 7.81 | 4.38 | 4.81 |
| Total Debt/Mcap(x) | 0.17 | 0.11 | 0.15 | 0.21 | 0.12 |
Compare Financial Ratios of peers of GENNEX LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GENNEX LABORATORIES | ₹368.2 Cr | -1.4% | -6.5% | 178.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹360,920.0 Cr | -2.3% | -6.5% | 55.3% | Stock Analytics | |
| CIPLA | ₹113,794.0 Cr | 4.1% | -4.8% | 55.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹106,860.0 Cr | 7.8% | 17.4% | 20.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,316.0 Cr | 4% | 0.8% | 29.4% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,380.9 Cr | -1.2% | -5.2% | 83.9% | Stock Analytics | |
GENNEX LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GENNEX LABORATORIES | -1.4% |
-6.5% |
178.6% |
| SENSEX | 0.9% |
1.5% |
23.6% |
You may also like the below Video Courses
